Dr. Leonard D. Genovese, MD

Dr. Genovese practices at MaineHealth Mid Coast Hospital in Brunswick, Maine, part of MaineHealth.

Dr. Genovese's NPI, 1366702805, was assigned on May 17, 2012. Dr. Genovese holds Maine license MD27061.

Dr. Genovese's primary practice is MaineHealth Mid Coast Hospital, at 123 Medical Center Drive, Brunswick, ME 04011 in Cumberland County. The practice phone is (207) 729-0181.

Dr. Genovese's primary practice is MaineHealth Mid Coast Hospital in Brunswick, Maine, part of MaineHealth. Dr. Genovese is also affiliated with MaineHealth Maine Medical Center. The medical group on file is MaineHealth Primary Care - Family Medicine - Portland. Dmand AI also links Dr. Genovese to 3 more hospitals, 1 clinical lab, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Genovese practices, 7 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Genovese's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dmand AI has Dr. Genovese's licenses on file in 3 states: Maine, District of Columbia and Virginia.

CMS data shows 1,468 Medicare services from Dr. Genovese across 18 procedure codes in 2024, for 802 Medicare patients. Medicare paid $39,174 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 802 Medicare patients who saw Dr. Genovese in 2024. The largest group is 75 to 84, with 292 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 19% are also on Medicaid. Their average risk score is 1.49, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Genovese's median patient age at 74, with 49% women.

In 2024, Dr. Genovese wrote 985 Medicare Part D claims for 168 patients. 71% of them were for generic drugs. CMS names the drug for 807 of them, across 17 drugs with 11 or more claims each, at $190,596 in total drug cost. In 2023, CMS named 143 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Genovese for performance year 2024, reported through an alternative payment model (APM). Dr. Genovese accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 33 general payments to Dr. Genovese from 15 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Abbott Laboratories paid the most, $196.